{"id":"W2921797044","doi":"10.1016/s2213-2600(18)30500-9","title":"Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Canada; Pfizer Canada; Bristol-Myers Squibb Canada; Merck Sharp and Dohme; AstraZeneca Canada; Genentech; Boehringer Ingelheim; MedImmune; Merck; AbbVie; Novartis; Roche; Eli Lilly and Company","keywords":"Medicine; Pembrolizumab; Internal medicine; Clinical endpoint; Adverse effect; Lung cancer; Oncology; Cohort; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001109198,0.0003998108,0.001076676,0.0001541609,0.0001106761,0.0000350936,0.0008198224,0.000111226,0.0006113311],"category_scores_gemma":[0.0000604604,0.0002282765,0.00002501517,0.000564159,0.0001653152,0.0002411852,0.0001387342,0.0005697433,0.00002679649],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002731582,"about_ca_system_score_gemma":0.0003237918,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002809795,"about_ca_topic_score_gemma":0.001050533,"domain_scores_codex":[0.9970008,0.00026819,0.0007170781,0.0007748154,0.0006763822,0.0005626951],"domain_scores_gemma":[0.99743,0.0001606022,0.0003653257,0.001658163,0.0001956423,0.0001902585],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3171513,0.007964385,0.6159433,0.0001666902,0.00050338,0.0001073663,0.006493806,0.00003578476,0.01879929,0.000005471114,0.01085676,0.02197251],"study_design_scores_gemma":[0.4361951,0.02120099,0.5275021,0.0009906795,0.0002641836,9.452983e-7,0.00123678,0.0001304871,0.0005456284,0.000004368037,0.01154758,0.0003811966],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894212,0.001311749,0.000003074737,0.001224081,0.0004455325,0.00448747,0.0001632994,0.0000614501,0.002882129],"genre_scores_gemma":[0.9928964,0.0001336723,0.00006611551,0.005220888,0.0007464505,0.0001936887,0.0001852412,0.00007540012,0.0004821479],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1190438,"threshold_uncertainty_score":0.9308846,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03974779098585332,"score_gpt":0.3540708388786967,"score_spread":0.3143230478928434,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}